

当施設の肝臓診療における治療成績論文:

当院では保険診療（通常診療）においてカルテ上に記録されたデータを用いて、後方視的に（振り返って）検討をして治療成績の評価・公開などを行い、実臨床への還元を行うことで常に治療成績の向上を目指しております。

このような臨床データ解析は新薬登場における治験と同様に当院のみならず全ての医療者において実臨床においては非常に重要な情報となります。そして最終的には本邦ならびに世界のガイドラインや診療コンセンサスにつながって将来肝臓患者さんが診療から得ることのできる大きな利益（診療成績改善）につながるものになっていきます。

個人情報扱いにおいては個人が特定されない形式を取っておりますが、検査や治療における情報の使用をご希望されない方は病院へお申し出頂くようになります。また多施設共同研究を含めて当院の臨床研究委員会で倫理的に問題がないことを確認された後に検討を行います。

また、当院では積極的に治験や医師主導型試験にも参加しております。詳しくは医師にお尋ねください。

C型肝炎治療後の発癌、肝臓治療後のC型肝炎治療について^{1 2}

糖尿病患者からの肝臓発癌について^{3 4}

肝臓の背景変化⁵

肝臓スクリーニングの重要性について^{6,7}

肝臓治療成績における筋肉の重要性^{8 9 10}

ALBIグレードの有用性^{11 12 13 14 15, 16 17 18}

mALBIグレードの有用性^{15 19 20 21 22 23 24 25 26 27}

肝臓に対する手術成績^{28 29 30 9}

肝臓に対するラジオ波治療成績^{28 31 32 17, 33, 34 35, 36}

肝臓に対する外科内科の共同治療成績^{37 38}

肝臓に対する肝動脈塞栓術治療成績^{39 40 13 14 41 42}

高齢者に対する肝臓治療^{31 43}

透析症例における肝癌治療成績⁴⁴

肝癌破裂症例の治療⁴⁵

切除不能肝癌における分子標的治療成績^{8 19 20 21 22 23 18 46 47 26 27 48 49 50 10, 51 43}

門脈圧亢進症合併からみた移植適応⁵²

亜鉛欠乏症と肝癌治療成績⁵³

ラジオ波治療支援・肝癌悪性度評価^{54 55 56 57 58 59 60 40}

肝癌の症例報告^{61 62 63 64 65 66}

(注：多施設共同研究も含まれます、また 2008 年以降の英文論文のみ抜粋して表示しています)

その他当院医師が関わった公的論文・書籍：

日本肝癌研究会診療ガイドライン論文^{67 68}

肝癌診療ガイドライン（編集参加）

COVID-19 感染下の肝癌診療に対する提言⁶⁹

原発性肝癌取り扱い規約 第 6 版補訂版（論文¹⁵採用）

肝癌診療マニュアル 第 4 版（編集参加）

肝臓専門医テキスト 第 3 版（編集参加）

<文献詳細>

1. Hiraoka A, Kumada T, Ogawa C, et al. Proposed a simple score for recommendation of scheduled ultrasonography surveillance for hepatocellular carcinoma after Direct Acting Antivirals: multicenter analysis. J Gastroenterol Hepatol 2019;34:436-441.
2. Ochi H, Hiraoka A, Hirooka M, et al. Direct-acting antivirals improve survival and recurrence rates after treatment of hepatocellular carcinoma within the Milan criteria. J Gastroenterol 2020.
3. Hiraoka A, Ochi M, Matsuda R, et al. Ultrasonography screening for hepatocellular carcinoma in

- Japanese patients with diabetes mellitus. *J Diabetes* 2016;8:640-6.
4. Nouse K, Furubayashi Y, Shiota S, et al. Early detection of hepatocellular carcinoma in patients with diabetes mellitus. *Eur J Gastroenterol Hepatol* 2020;32:877-881.
 5. Hiraoka A, Hidaka S, Shimizu Y, et al. Recent trends of Japanese hepatocellular carcinoma due to HCV in aging society. *Hepatogastroenterology* 2012;59:1893-5.
 6. Toyoda H, Kumada T, Tada T, et al. Impact of hepatocellular carcinoma aetiology and liver function on the benefit of surveillance: A novel approach for the adjustment of lead-time bias. *Liver Int* 2018;38:2260-2268.
 7. Yamago H, Hiraoka A, Murakami T, et al. Ultrasonography surveillance improves prognosis of patients with hepatocellular carcinoma. *Mol Clin Oncol* 2019;11:325-330.
 8. Hiraoka A, Hirooka M, Koizumi Y, et al. Muscle volume loss as a prognostic marker in hepatocellular carcinoma patients treated with sorafenib. *Hepatol Res* 2017;47:558-565.
 9. Hiraoka A, Otsuka Y, Kawasaki H, et al. Impact of muscle volume and muscle function decline in patients undergoing surgical resection for hepatocellular carcinoma. *J Gastroenterol Hepatol* 2018;33:1271-1276.
 10. Hiraoka A, Kumada T, Kariyama K, et al. Clinical importance of muscle volume in lenvatinib treatment for hepatocellular carcinoma: Analysis adjusted with inverse probability weighting. *J Gastroenterol Hepatol* 2020.
 11. Hiraoka A, Kumada T, Michitaka K, et al. Usefulness of albumin-bilirubin grade for evaluation of prognosis of 2584 Japanese patients with hepatocellular carcinoma. *J Gastroenterol Hepatol* 2016;31:1031-6.
 12. Hiraoka A, Kumada T, Michitaka K, et al. Is there a survival benefit in interventional radiology for hepatocellular carcinoma in patients with Child-Pugh C liver cirrhosis?: A multicenter study. *Hepatol Res* 2016;46:521-8.
 13. Hiraoka A, Kumada T, Nouse K, et al. Proposed New Sub-Grouping for Intermediate-Stage Hepatocellular Carcinoma Using Albumin-Bilirubin Grade. *Oncology* 2016;91:153-61.
 14. Hiraoka A, Kumada T, Kudo M, et al. Hepatic Function during Repeated TACE Procedures and Prognosis after Introducing Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: Multicenter Analysis. *Dig Dis* 2017;35:602-610.
 15. Hiraoka A, Kumada T, Kudo M, et al. Albumin-Bilirubin (ALBI) Grade as Part of the Evidence-Based Clinical Practice Guideline for HCC of the Japan Society of Hepatology: A Comparison with the Liver Damage and Child-Pugh Classifications. *Liver Cancer* 2017;6:204-215.
 16. Kariyama K, Nouse K, Toyoda H, et al. Utility of FIB4-T as a Prognostic Factor for Hepatocellular Carcinoma. *Cancers (Basel)* 2019;11.
 17. Hiraoka A, Kumada T, Hirooka M, et al. A better method for assessment of hepatic function in hepatocellular carcinoma patients treated with radiofrequency ablation: Usefulness of albumin-bilirubin grade. *Hepatol Res* 2018;48:E61-E67.
 18. Tada T, Kumada T, Toyoda H, et al. Impact of albumin-bilirubin grade on survival in patients with hepatocellular carcinoma who received sorafenib: An analysis using time-dependent receiver operating characteristic. *J Gastroenterol Hepatol* 2019;34:1066-1073.
 19. Hiraoka A, Kumada T, Atsukawa M, et al. Early Relative Change in Hepatic Function with Lenvatinib

- for Unresectable Hepatocellular Carcinoma. *Oncology* 2019;97:334-340.
20. Hiraoka A, Kumada T, Atsukawa M, et al. Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions-Multicenter analysis. *Cancer Med* 2019;8:3719-3728.
 21. Hiraoka A, Kumada T, Atsukawa M, et al. Important Clinical Factors in Sequential Therapy Including Lenvatinib against Unresectable Hepatocellular Carcinoma. *Oncology* 2019:1-9.
 22. Hiraoka A, Kumada T, Kariyama K, et al. Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions: Multicenter analysis. *Cancer Med* 2019;8:137-146.
 23. Hiraoka A, Kumada T, Kariyama K, et al. Therapeutic potential of lenvatinib for unresectable hepatocellular carcinoma in clinical practice: Multicenter analysis. *Hepatol Res* 2019;49:111-117.
 24. Hiraoka A, Kumada T, Michitaka K, et al. Newly Proposed ALBI Grade and ALBI-T Score as Tools for Assessment of Hepatic Function and Prognosis in Hepatocellular Carcinoma Patients. *Liver Cancer* 2019;8:312-325.
 25. Hiraoka A, Kumada T, Tsuji K, et al. Validation of Modified ALBI Grade for More Detailed Assessment of Hepatic Function in Hepatocellular Carcinoma Patients: A Multicenter Analysis. *Liver Cancer* 2019;8:121-129.
 26. Hiraoka A, Kumada T, Fukunishi S, et al. Post-Progression Treatment Eligibility of Unresectable Hepatocellular Carcinoma Patients Treated with Lenvatinib. *Liver Cancer* 2020;9:73-83.
 27. Hiraoka A, Kumada T, Tada T, et al. Nutritional Index as Prognostic Indicator in Patients Receiving Lenvatinib Treatment for Unresectable Hepatocellular Carcinoma. *Oncology* 2020:1-8.
 28. Hiraoka A, Horiike N, Yamashita Y, et al. Efficacy of radiofrequency ablation therapy compared to surgical resection in 164 patients in Japan with single hepatocellular carcinoma smaller than 3 cm, along with report of complications. *Hepatogastroenterology* 2008;55:2171-4.
 29. Hiraoka A, Michitaka K, Kumada T, et al. Validation and Potential of Albumin-Bilirubin Grade and Prognostication in a Nationwide Survey of 46,681 Hepatocellular Carcinoma Patients in Japan: The Need for a More Detailed Evaluation of Hepatic Function. *Liver Cancer* 2017;6:325-336.
 30. Tada T, Kumada T, Toyoda H, et al. Role of hepatic resection in patients with intermediate-stage hepatocellular carcinoma: A multicenter study from Japan. *Cancer Sci* 2017;108:1414-1420.
 31. Hiraoka A, Michitaka K, Horiike N, et al. Radiofrequency ablation therapy for hepatocellular carcinoma in elderly patients. *J Gastroenterol Hepatol* 2010;25:403-7.
 32. Hirooka M, Ochi H, Koizumi Y, et al. Local recurrence of hepatocellular carcinoma in the tumor blood drainage area following radiofrequency ablation. *Mol Clin Oncol* 2014;2:182-186.
 33. Hirooka M, Ochi H, Hiraoka A, et al. Multipolar versus monopolar radiofrequency ablation for hepatocellular carcinoma in the caudate lobe: Results of a propensity score analysis. *Hepatol Res* 2017;47:658-667.
 34. Hirooka M, Koizumi Y, Imai Y, et al. Assessment of a needle-tracking system for bipolar radiofrequency ablation. *J Med Ultrason (2001)* 2016;43:185-91.
 35. Maeda M, Saeki I, Sakaida I, et al. Complications after Radiofrequency Ablation for Hepatocellular Carcinoma: A Multicenter Study Involving 9,411 Japanese Patients. *Liver Cancer* 2020;9:50-62.
 36. Kariyama K, Nouse K, Wakuta A, et al. Treatment of Intermediate-Stage Hepatocellular Carcinoma in Japan: Position of Curative Therapies. *Liver Cancer* 2020;9:41-49.

37. Hiraoka A, Tazuya N, Hidaka S, et al. Hepatic resection assisted by ablative therapy for advanced hepatocellular carcinoma. *Hepatogastroenterology* 2011;58:955-9.
38. Hiraoka A, Hirooka M, Ochi H, et al. Combination of Resection and Ablative Treatment for Hepatocellular Carcinoma: Usefulness of Complementary Radiofrequency Ablation. *Oncology* 2019;96:242-251.
39. Hiraoka A, Horiike N, Yamashita Y, et al. Risk factors for death in 224 cases of hepatocellular carcinoma after transcatheter arterial chemoembolization. *Hepatogastroenterology* 2009;56:213-7.
40. Hiraoka A, Ishimaru Y, Kawasaki H, et al. Tumor Markers AFP, AFP-L3, and DCP in Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization. *Oncology* 2015;89:167-74.
41. Izumoto H, Hiraoka A, Ishimaru Y, et al. Validation of Newly Proposed Time to Transarterial Chemoembolization Progression in Intermediate-Stage Hepatocellular Carcinoma Cases. *Oncology* 2017;93 Suppl 1:120-126.
42. Hiraoka A, Michitaka K, Kumada T, et al. Prediction of Prognosis of Intermediate-Stage HCC Patients: Validation of the Tumor Marker Score in a Nationwide Database in Japan. *Liver Cancer* 2019;8:403-411.
43. Tada T, Kumada T, Hiraoka A, et al. Safety and efficacy of lenvatinib in elderly patients with unresectable hepatocellular carcinoma: A multicenter analysis with propensity score matching. *Hepatol Res* 2020;50:75-83.
44. Hiraoka A, Kumada T, Michitaka K, et al. Clinical features of hemodialysis patients treated for hepatocellular carcinoma: Comparison between resection and radiofrequency ablation. *Mol Clin Oncol* 2017;6:455-461.
45. Hiraoka A, Kawamura T, Aibiki T, et al. Prognosis and therapy for ruptured hepatocellular carcinoma: problems with staging and treatment strategy. *Eur J Radiol* 2015;84:366-71.
46. Koizumi Y, Hirooka M, Hiraoka A, et al. Lenvatinib-induced thyroid abnormalities in unresectable hepatocellular carcinoma. *Endocr J* 2019;66:787-792.
47. Yukimoto A, Hirooka M, Hiraoka A, et al. Using ALBI score at the start of sorafenib treatment to predict regorafenib treatment candidates in patients with hepatocellular carcinoma. *Jpn J Clin Oncol* 2019;49:42-47.
48. Tada T, Kumada T, Hiraoka A, et al. Neutrophil-to-lymphocyte ratio is associated with survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib. *Liver Int* 2020;40:968-976.
49. Hiraoka A, Kumada T, Tada T, et al. Therapeutic efficacy of ramucirumab after lenvatinib for post-progression treatment of unresectable hepatocellular carcinoma. *Gastroenterol Rep* 2020 (e-pub ahead of print) doi: 10.1093/gastro/goaa042.
50. Chuma M, Uojima H, Hiraoka A, et al. Analysis of efficacy of lenvatinib treatment in highly advanced hepatocellular carcinoma with tumor thrombus in the main trunk of the portal vein or tumor with more than 50% liver occupation: a multicenter analysis. *Hepatol Res* 2020.
51. Tada T, Kumada T, Hiraoka A, et al. Platelet-lymphocyte ratio predicts survival in patients with hepatocellular carcinoma who receive lenvatinib: an inverse probability weighting analysis. *Eur J Gastroenterol Hepatol* 2020.
52. Kawakami T, Hiraoka A, Michitaka K, et al. Importance of Screening for Esophagogastric Varices in Naïve Hepatocellular Carcinoma Patients within Milan Criteria: Indicator for Liver Transplantation.

Dig Surg 2017;34:429-435.

53. Hiraoka A, Nagamatsu K, Izumoto H, et al. Zinc deficiency as an independent prognostic factor for patients with early hepatocellular carcinoma due to hepatitis virus. *Hepatol Res* 2020;50:92-100.
54. Hiraoka A, Hirooka M, Koizumi Y, et al. Modified technique for determining therapeutic response to radiofrequency ablation therapy for hepatocellular carcinoma using US-volume system. *Oncol Rep* 2010;23:493-7.
55. Hiraoka A, Ichiryu M, Tazuya N, et al. Clinical translation in the treatment of hepatocellular carcinoma following the introduction of contrast-enhanced ultrasonography with Sonazoid. *Oncol Lett* 2010;1:57-61.
56. Hiraoka A, Kume M, Miyagawa M, et al. Diagnostic value of sonazoid for hepatic metastasis: comparison with FDG PET/CT. *Hepatogastroenterology* 2010;57:1237-40.
57. Kan M, Hiraoka A, Uehara T, et al. Evaluation of contrast-enhanced ultrasonography using perfluorobutane (Sonazoid((R))) in patients with small hepatocellular carcinoma: comparison with dynamic computed tomography. *Oncol Lett* 2010;1:485-488.
58. Hiraoka A, Hiasa Y, Onji M, et al. New contrast enhanced ultrasonography agent: impact of Sonazoid on radiofrequency ablation. *J Gastroenterol Hepatol* 2011;26:616-8.
59. Hiraoka A, Hirooka M, Ochi H, et al. Importance of screening for synchronous malignant neoplasms in patients with hepatocellular carcinoma: impact of FDG PET/CT. *Liver Int* 2013;33:1085-91.
60. Ochi H, Hirooka M, Hiraoka A, et al. 18F-FDG-PET/CT predicts the distribution of microsatellite lesions in hepatocellular carcinoma. *Mol Clin Oncol* 2014;2:798-804.
61. Hiraoka A, Horiike N, Koizumi Y, et al. Brain metastasis from hepatocellular carcinoma treated with a cyber-knife. *Intern Med* 2008;47:1993-6.
62. Ikegawa S, Hiraoka A, Shimizu Y, et al. Hepatocellular carcinoma in a case of Wilson's disease treated with radiofrequency ablation therapy. *Intern Med* 2011;50:1433-7.
63. Ochi H, Hiraoka A, Uehara T, et al. Abdominal imaging findings of a patient with hepatocellular carcinoma associated with glycogen storage disease type 1a. *Intern Med* 2011;50:2317-22.
64. Ochi H, Hiraoka A, Michitaka K. Discussion regarding the method of screening for hepatocellular carcinoma in glycogen storage disease type 1a. *Intern Med* 2012;51:1813.
65. Hirooka M, Ochi H, Hiraoka A, et al. Destructive Thyroiditis Induced by Lenvatinib in Three Patients with Hepatocellular Carcinoma. *Intern Med* 2019;58:791-795.
66. Adachi T, Hiraoka A, Okazaki H, et al. Exacerbation of psoriasis vulgaris by sorafenib treatment for hepatocellular carcinoma. *Clin J Gastroenterol* 2020;13:891-895.
67. Kudo M, Matsui O, Izumi N, et al. JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan. *Liver Cancer* 2014;3:458-68.
68. Kudo M, Matsui O, Izumi N, et al. Transarterial chemoembolization failure/refractoriness: JSH-LCSGJ criteria 2014 update. *Oncology* 2014;87 Suppl 1:22-31.
69. Kudo M, Kurosaki M, Ikeda M, et al. Treatment of hepatocellular carcinoma during the COVID-19 outbreak: The Working Group report of JAMTT-HCC. *Hepatol Res* 2020.